MILAB s.r.o.

The trials here

What the 9 trials at this site are about, from their registry records.

Conditions

• Prostate cancer9 trials

Phase

• Phase 38 trials
• Phase 21 trial

Status

• Active, not recruiting9 trials

Lead sponsor

• Pfizer4 trials
• AstraZeneca2 trials
• Astellas Pharma Global Development, Inc.1 trial
• Celgene1 trial
• Janssen Pharmaceutica N.V., Belgium1 trial

Running trials

• Recruiting

  This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

  NCT07028853· Phase 3· Pfizer· Source

• Active, not recruiting

  A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

  NCT06764485· Phase 3· Celgene· Source

• Active, not recruiting

  A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).

  NCT06551324· Phase 3· Pfizer· Source

• Active, not recruiting

  Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

  NCT04821622· Phase 3· Pfizer· Source

• Active, not recruiting

  A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer

  NCT04557059· Phase 3· Janssen Pharmaceutica N.V., Belgium· Source

• Active, not recruiting

  Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency

  NCT04493853· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

  NCT03732820· Phase 3· AstraZeneca· Source

• Active, not recruiting

  A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

  NCT02960022· Phase 2· Astellas Pharma Global Development, Inc.· Source

• Active, not recruiting

  Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

  NCT02319837· Phase 3· Pfizer· Source